Navigation Links
Genstruct and Sirtris Pharmaceuticals Win Bio-IT World's Best Practices Award
Date:4/30/2008

Causal Network Modeling Provides Powerful Approach to Modeling Complex

Biological Systems for Type 2 Diabetes

CAMBRIDGE, Mass., April 30 /PRNewswire/ -- Genstruct Inc., a systems biology company focused on identifying molecular mechanisms, networks and biomarkers to better understand large scale biology, today announced that its joint collaboration with Sirtris Pharmaceuticals, Inc. (Nasdaq: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, has won Bio-IT World magazine's 2008 Best Practices Award in the Drug Discovery & Development category. The project was focused on discovering mechanisms of action (MOA) for Type 2 diabetes.

The two companies collaborated to further characterize the molecular MOA of Sirt1 activating compounds. In blinded analysis, Genstruct's causal network modeling (CNM) approach concluded that the strongest hypothesis for the results seen in the Sirtris Type 2 diabetes study was caloric restriction (CR) -- showing that Sirtris' SIRT1 activators are mimicking the effects of CR. These results were confirmed by in vitro and in vivo experimentations.

"We are honored that our collaboration with Sirtris has been recognized for our unique approach to modeling complex biological systems," said Dr. Keith O. Elliston, president and CEO at Genstruct. "Using our CNM platform, we were able to help develop a deep understanding of the SIRT1 pathway and allowed Sirtris to efficiently analyze a vast quantity of data. Sirtris has been a valued research partner for our firm."

Genstruct's unique CNM platform for systems biology has been designed to integrate and model data from multiple large-scale measurement modalities and has been successfully applied to biomarker discovery, MOA definition and drug safety assessment.

Genstruct and Sirtris received this award on April 29 at the 2008 Best Practices VIP Gala Awards Dinner at the World Trade Center in Boston, Mass. Fifty-five entries were submitted and were judged by a panel of experts based on the nominees' novel and innovative uses of technology to improve the efficiency and economics of R&D, drug discovery and clinical research and trials.

About Genstruct

Founded in 2002, Genstruct is a biotechnology company focused on elucidating the complexity of biology for the development of successful therapeutics. By modeling the components within the whole biological system, Genstruct delivers a deep molecular understanding of diseases and drug action, as well as mechanistic biomarkers to accelerate drug discovery and development programs. Genstruct engages in internal discovery and external development partnerships with top tier pharmaceutical companies, which apply systems biology in the areas of oncology, metabolic disorders, cardiovascular diseases and inflammation. The privately held company is based in Cambridge, Mass. For more information, please visit http://www.genstruct.com.

Genstruct and the Genstruct logo are registered trademarks and Molecular Epistemics, Knowledge Assembly, and Epistemics Engine are trademarks of Genstruct, Inc. All other trademarks or registered trademarks are properties of their respective owners.

Contacts:

Karen Higgins

A & E Communications for Genstruct

(610) 831-5723

khiggins@aandecomm.com


'/>"/>
SOURCE Genstruct Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genstruct CEO, Dr. Keith Elliston, Invited to Speak at Oncology Clinical Trial Summit
2. Genstructs Andrea Matthews Selected for Mass High Techs People to Watch Under 30
3. GlaxoSmithKline to Acquire Sirtris Pharmaceuticals, a World Leader in Sirtuin Research and Development
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... States multicenter, prospective clinical study that demonstrates the accuracy of the FebriDx® ... identifying clinically significant acute bacterial and viral respiratory tract infections by testing ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... any gene in its endogenous context, enabling overexpression experiments and avoiding the use ... with small RNA guides is transformative for performing systematic gain-of-function studies. , ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. 11, ... Research, London (ICR) and University of ... SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma (MM), ... nine . The University of Leeds ... funded by Myeloma UK, and ICR will perform the testing ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that ... Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los ...
Breaking Biology Technology:
(Date:4/5/2017)... Allen Institute for Cell Science today announces the launch ... dynamic digital window into the human cell. The website ... deep learning to create predictive models of cell organization, ... suite of powerful tools. The Allen Cell Explorer will ... resources created and shared by the Allen Institute for ...
(Date:4/5/2017)... 4, 2017 KEY FINDINGS The ... at a CAGR of 25.76% during the forecast period ... primary factor for the growth of the stem cell ... MARKET INSIGHTS The global stem cell market ... and geography. The stem cell market of the product ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
Breaking Biology News(10 mins):